AbbVie (ABBV) Surged To A New High On Phase 2 Study Results

AbbVie (ABBV) announced Thursday morning that its Phase 2b study of upadacitinib met the primary endpoint and all skin and itch-specific secondary endpoints.

from RTT - Before the Bell http://ift.tt/2jb2Ogq
via IFTTT